Novartis AG (SW:NOVN) — Market Cap & Net Worth
Market Cap & Net Worth: Novartis AG (NOVN)
Novartis AG (SW:NOVN) has a market capitalization of $285.29 Billion (CHF225.66 Billion) as of April 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #69 globally and #2 in its home market, demonstrating a -3.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novartis AG's stock price CHF118.26 by its total outstanding shares 1908151679 (1.91 Billion).
Novartis AG Market Cap History: 2015 to 2026
Novartis AG's market capitalization history from 2015 to 2026. Data shows growth from $120.87 Billion to $285.29 Billion (8.10% CAGR).
Index Memberships
Novartis AG is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
STOXX Europe Large 200 EUR Price
LCXP
|
$5.55 Trillion | 4.35% | #3 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$5.55 Trillion | 4.35% | #3 of 182 |
Weight: Novartis AG's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novartis AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novartis AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.63x
Novartis AG's market cap is 4.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.05x
Novartis AG's market cap is 18.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $108.01 Billion | $49.44 Billion | $6.71 Billion | 2.18x | 16.09x |
| 2017 | $125.33 Billion | $43.40 Billion | $7.70 Billion | 2.89x | 16.27x |
| 2018 | $133.48 Billion | $46.10 Billion | $12.61 Billion | 2.90x | 10.58x |
| 2019 | $171.53 Billion | $48.68 Billion | $11.73 Billion | 3.52x | 14.62x |
| 2020 | $162.29 Billion | $49.90 Billion | $8.07 Billion | 3.25x | 20.10x |
| 2021 | $162.10 Billion | $43.97 Billion | $24.02 Billion | 3.69x | 6.75x |
| 2022 | $176.29 Billion | $43.46 Billion | $6.96 Billion | 4.06x | 25.35x |
| 2023 | $197.32 Billion | $46.66 Billion | $14.85 Billion | 4.23x | 13.29x |
| 2024 | $213.98 Billion | $51.72 Billion | $11.94 Billion | 4.14x | 17.92x |
| 2025 | $264.40 Billion | $57.13 Billion | $14.65 Billion | 4.63x | 18.05x |
Competitor Companies of NOVN by Market Capitalization
Companies near Novartis AG in the global market cap rankings as of April 18, 2026.
Key companies related to Novartis AG by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $829.71 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #19 globally with a market cap of $564.21 Billion USD.
- Roche Holding AG (SW:ROP): Ranked #64 globally with a market cap of $254.60 Billion USD ( CHF201.38 Billion CHF).
- AbbVie Inc (NYSE:ABBV): Ranked #33 globally with a market cap of $368.45 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $829.71 Billion | $927.03 |
| #19 | Johnson & Johnson | NYSE:JNJ | $564.21 Billion | $234.18 |
| #64 | Roche Holding AG | SW:ROP | $254.60 Billion | CHF320.00 |
| #33 | AbbVie Inc | NYSE:ABBV | $368.45 Billion | $208.38 |
Novartis AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Novartis AG's market cap moved from $120.87 Billion to $ 285.29 Billion, with a yearly change of 8.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF285.29 Billion | +7.90% |
| 2025 | CHF264.40 Billion | +23.56% |
| 2024 | CHF213.98 Billion | +8.44% |
| 2023 | CHF197.32 Billion | +11.93% |
| 2022 | CHF176.29 Billion | +8.75% |
| 2021 | CHF162.10 Billion | -0.11% |
| 2020 | CHF162.29 Billion | -5.39% |
| 2019 | CHF171.53 Billion | +28.50% |
| 2018 | CHF133.48 Billion | +6.51% |
| 2017 | CHF125.33 Billion | +16.04% |
| 2016 | CHF108.01 Billion | -10.65% |
| 2015 | CHF120.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Novartis AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $285.29 Billion USD |
| MoneyControl | $285.29 Billion USD |
| MarketWatch | $285.29 Billion USD |
| marketcap.company | $285.29 Billion USD |
| Reuters | $285.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more